(Q44045671)

29 November 2017

title

Aromatase inhibitors for the endocrine adjuvant treatment of breast cancer (English)

1 reference

29 November 2017

Peter Ravdin

1

1 reference

29 November 2017

language of work or name

English

0 references

publication date

1 June 2002

1 reference

29 November 2017

1 reference

29 November 2017

volume

359

1 reference

29 November 2017

issue

9324

1 reference

29 November 2017

page(s)

2126-2127

1 reference

Prognostic significance of progesterone receptor levels in estrogen receptor-positive patients with metastatic breast cancer treated with tamoxifen: results of a prospective Southwest Oncology Group study

29 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2909111-0

7 January 2021

Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2909111-0

7 January 2021

Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2909111-0

7 January 2021

Tamoxifen in the treatment of breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2909111-0

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2909111-0

7 January 2021

Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2909111-0

7 January 2021

10.1016/S0140-6736(02)09111-0

Identifiers

DOI

1 reference

29 November 2017

1 reference